A Comprehensive Review of Pacritinib in Myelofibrosis
- 14 September 2015
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 11 (20) , 2819-2830
Abstract
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis. However, the association of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treatment choices in myelofibrosis. Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis. This article examines the role of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the clinical development of pacritinib as a new therapy for myelofibrosis.Keywords
This publication has 62 references indexed in Scilit:
- Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosisBlood Cancer Journal, 2014
- JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsJAK-STAT, 2013
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- Primary myelofibrosis: 2013 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2013
- Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in miceBlood, 2012
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaBlood Cancer Journal, 2011
- Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7–induced signalingProceedings of the National Academy of Sciences, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- Outcome of Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2010
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005